Coronary revascularization in diabetic patients: Current state of evidence

Mukesh Singh1, Rohit Arora, Vamsi Kodumuri

  • 1Division of Cardiology, Department of Internal Medicine, Rosalind Franklin University of Medicine & Science/The Chicago Medical School, North Chicago, Illinois, USA.

Insights

Diabetic patients undergoing coronary revascularization have worse outcomes. Optimal strategies for percutaneous coronary intervention versus surgical revascularization in diabetics with multivessel disease require further evidence.

Area of Science:

  • Cardiology
  • Diabetology
  • Interventional Cardiology

Background:

  • Diabetic patients represent a growing population undergoing coronary revascularization.
  • These patients exhibit poorer outcomes compared to non-diabetic individuals.
  • Current evidence for optimal revascularization strategy in diabetics is limited.

Purpose of the Study:

  • To summarize the current evidence on coronary revascularization strategies for diabetic patients.
  • To address the uncertainty surrounding the optimal approach in the context of advancing treatments.
  • To provide data to guide decision-making for diabetic patients with multivessel coronary artery disease.

Main Methods:

  • Review of current evidence on percutaneous coronary intervention (PCI) and surgical revascularization.
  • Analysis of data concerning drug-eluting stents and newer antiplatelet agents.
  • Focus on diabetic patients with multivessel coronary artery disease.

Main Results:

  • Diabetic patients undergoing PCI or surgical revascularization have worse outcomes.
  • The optimal revascularization strategy remains unclear due to advancements in both PCI and surgical techniques.
  • Limited data exists for current treatment choices in this specific population.

Conclusions:

  • The optimal coronary revascularization strategy for diabetic patients with multivessel coronary artery disease is not definitively established.
  • Further research is needed to guide the choice between PCI and surgical revascularization in this high-risk group.
  • Advancements in pharmacotherapy and technology necessitate updated evidence for clinical decision-making.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...